The Trump administration is reportedly planning to roll out a five-year pilot program that would give obese people on Medicare and Medicaid access to groundbreaking and increasingly popular weight loss drugs, including Ozempic and Zepbound.

According to The Washington Post , the plan is being developed by the Centers for Medicare and Medicaid Services and would be run through the Center for Medicare and Medicaid Innovation (CMMI) testing lab, which aims to lower costs and improve health outcomes by trying new ways to pay for health care.

How would the pilot work?

Big picture view:

The pilot program would allow state Medicaid programs and Medicare Part D insurance plans to choose to cover Ozempic, Wegovy, Mounjaro and Zepbound for patients for "weight management" purposes, the pa

See Full Page